ArticleSkeletal radiology2015
Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy.
Article in Skeletal radiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Denosumab for Effective Tumor Size Reduction in Patients With Giant Cell Tumors of the Bone: A Systematic Review and Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Article
- Significance of Biogenetic Markers in Giant Cell Tumor Differentiation and Prognosis: A Narrative Review.Diagnostics (Basel, Switzerland) · 2024Review
- Percutaneous radiofrecuency thermal ablation for management of recurrent bone giant cell tumour.Quantitative imaging in medicine and surgery · 2024Article
- Efficacy and safety of denosumab de‑escalation in giant cell tumor of bone.Oncology letters · 2024Article
- Reshrinkage of Giant-Cell Tumor of the Bone in the Thoracic Vertebrae after Resumption of Denosumab Treatment: A Case Report.Spine surgery and related research · 2024Article
- Denosumab for giant cell tumors of bone from 2010 to 2022: a bibliometric analysis.Clinical and experimental medicine · 2023Review
- Denosumab combined with precision radiotherapy for recurrent giant cell tumor of the thoracic spine: a case report and literature review.Frontiers in neurology · 2023Article
- Metastasis in Sinonasal Region Revealing a Silent Primary: A Series of 2 Cases with Review of Literature.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022Article
- Review
- Evaluating the Optimal Management of Inoperable Giant Cell Tumors of the Spine: A Systematic Review and Meta-Analysis.Cancers · 2022Review
- Rapid Recurrence of Giant Cell Tumour of C2 Vertebra After Long-Term Denosumab Following Surgical Resection.Cureus · 2022Article
- The Activation of PDGFRβ on Mononuclear Stromal/Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment. An Immunohistochemical Study of Five Cases.Pathology oncology research : POR · 2022Article
- Giant cell tumors of the sacrum: is non-operative treatment effective?European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2021Article
- Multiple Pulmonary Metastases of Recurrent Giant Cell Tumor of Bone with Expression of VEGFR-2 Successfully Controlled by Denosumab and Apatinib: A Case Report and Literature Review.Cancer management and research · 2021Article
- Radiological findings of denosumab treatment for giant cell tumours of bone.Skeletal radiology · 2020Review
- Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls.Frontiers in oncology · 2020Review
- Denosumab does not decrease the risk of lung metastases from bone giant cell tumour.International orthopaedics · 2019Article
- Total spondylectomy for Enneking stage III giant cell tumor of the mobile spine.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2018Article
- Denosumab: a potential treatment option for aneurysmal bone cyst of the atlas.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of rapid recurrence of a giant cell tumor (GCT) of the distal radius in a 24-year-old woman following the cessation of long-term denosumab therapy. GCT of bone is a histologically benign tumor with multinucleated giant cells on a background of mononuclear giant cells usually presenting as a well-defined epi-metaphyseal lytic lesion without sclerotic margins. Denosumab, a monoclonal antibody to the receptor activator of nuclear factor kappa-B ligand (RANKL), has proven to be an effective neoadjuvant treatment for GCT. The tumor in this case had demonstrated a good response with sustained control for over 2 years while on denosumab therapy. However, within 2 months of cessation of therapy, the tumor demonstrated rapid recurrence and progression with growth, osteolysis, and increased soft tissue component. Despite reinitiating denosumab therapy, there was progressive tumor growth and destruction, ultimately necessitating below-the-elbow amputation. This case illustrates the need for maintenance of denosumab therapy for GCT of bone or definitive surgical treatment prior to its cessation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.